Biohaven Announces Pricing of $250 Million Public Offering of Common Shares
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/28/2026
- Wall St set for subdued open as tech rally pauses before Warsh's speech
- PayPal tumbles as Advent, Stripe said to drop $50 bln pursuit
- Oil drifts lower as Hormuz flows balance slow progress in Iran diplomacy
- Dollar heads for weekly gain as Warsh remarks awaited
- Chevron stock rises on report of Venezuela oil deal talks
- First Financial to acquire Hickory Point Bank in $111.3M deal
- Affirm Holdings (AFRM) Tops Q4 EPS by $3.77, Beats on Revenue
- Nasdaq, S&P 500 lifted by Nvidia's forecast; investors eye speech by Fed's Warsh
- Ovintiv adds 41,000 acres in Permian and Montney deals
- Russia says it could strike UK military targets in response to Kyiv's use of British missiles
Biohaven Pharmaceutical Holding (BHVN) PT Raised to $68 at JPMorgan
October 3, 2024 6:01 AM EDTJPMorgan analyst Tessa Romero raised the price target on Biohaven Pharmaceutical Holding (NYSE: BHVN) to $68.00 (from $55.00) while maintaining a Overweight rating.
The analyst comments "We are updating our model following Biohavens updates last week around their troriluzole program in spinocerebellar ataxia (SCA), where the company expects to complete resubmission of an NDA for the treatment of all SCA genotypes... More
